



Department of Health and Human Services
Maine Center for Disease Control and Prevention
286 Water Street
11 State House Station
Augusta, Maine 04333-0011
Tel.: (207) 287-8016; Fax: (207) 287-9058
TTY Users: Dial 711 (Maine Relay)

To: Maine Vaccines for Children Providers

From: Maine Immunization Program

Subject: GARDASIL 9® Guidance

Date: June 24, 2015

With an increase of calls made to the Maine Immunization Program in regards to the recent availability of the GARDASIL 9®, we are providing you with detailed guidance on the vaccine. We hope that you find this beneficial.

The Advisory Committee of Immunization Practices (ACIP) is now recommending Gardasil 9 as one of the three HPV vaccines that can be used for vaccination. The Gardasil 9 has been approved for use in both males and females.

Health Impact

Gardasil 9 provides protection against five additional types of HPV. Since the five additional types in HPV 9 account for a higher proportion of HPV-associated cancers in females compared with males and cause cervical precancers, the additional protection from HPV 9 will mostly benefit females.

The additional benefit from HPV 9 is preventing an additional 15% of cervical cancers in women, and 4% of all HPV-related cancers in boys and men.

ACIP Recommendations for Use

Routine HPV vaccination should be initiated at age 11 or 12 years. The vaccination series can be started as early as 9 years. Gardasil 9 can be used up to age 26 for females and up to age 21 for males. It is recommended that males receive the HPV 4 (as long as this formulation is available) or HPV 9.

Protection

In girls and women 9 through 26 years of age, GARDASIL 9 helps protect against:

- Cervical cancer
- Vulvar and vaginal cancers

- Anal cancer
- Precancerous cervical, vulvar, vaginal and anal lesions
- Genital warts

In boys 9 through 21 years of age, GARDASIL 9 helps protect against:

- Anal cancer
- Precancerous anal lesions
- Genital warts

These diseases have many causes. Most of the time, these diseases are caused by nine types of HPV:

HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58. GARDASIL 9 only protects against diseases caused by these nine types of HPV.

ACIP Recommendations for Administration

The HPV 9 is administered in a 3-dose schedule. The second dose is administered at least 1 to 2 months after the first dose, and the third dose at least 6 months after the first dose. **If the vaccine schedule is interrupted, the vaccination series does not need to be restarted.**

Interchangeability

If providers do not know or do not have available the HPV product previously administered, or are in settings transitioning to HPV 9, any available HPV vaccine product may be used to continue or complete the series for females for protection against HPV 16 and 18; HPV 9 or HPV 4 may be used to continue or complete the series for males.

Please visit the following links for more information:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm>

<http://www.cdc.gov/std/tg2015/tg-2015->

[print.pdf//////////](#)

<http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv-gardasil-9.pdf>

Should you have any questions regarding this please contact us at 287-3746.

As always, thank you for your commitment to keeping Maine's children free of vaccine preventable disease.